James M. Martinez

3.6k total citations · 1 hit paper
47 papers, 2.5k citations indexed

About

James M. Martinez is a scholar working on Psychiatry and Mental health, Pharmacology and Pathology and Forensic Medicine. According to data from OpenAlex, James M. Martinez has authored 47 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Psychiatry and Mental health, 16 papers in Pharmacology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in James M. Martinez's work include Migraine and Headache Studies (19 papers), Treatment of Major Depression (13 papers) and Trigeminal Neuralgia and Treatments (8 papers). James M. Martinez is often cited by papers focused on Migraine and Headache Studies (19 papers), Treatment of Major Depression (13 papers) and Trigeminal Neuralgia and Treatments (8 papers). James M. Martinez collaborates with scholars based in United States, United Kingdom and Italy. James M. Martinez's co-authors include Lauren B. Marangell, Holly A. Zboyan, Lucy J. Puryear, Barbara Kertz, Michael J. Robinson, Tina M. Oakes, James M. Russell, Laurie M. Brown, Timothy J. Teyler and Stephen R. Wisniewski and has published in prestigious journals such as New England Journal of Medicine, American Journal of Psychiatry and Neurology.

In The Last Decade

James M. Martinez

45 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression

2007 567 citations Joseph R. Calabrese, Lauren B. Marangell et al. profile →

Peers

James M. Martinez

PMH

PHARM

PHYSI

PFM

NEURO

Virginia L. Stauffer United States

Elyse Stock United States

J. Craig Nelson United States

David Michelson United States

Jan Balldin Sweden

Luigi Alberto Pini Italy

Teruhiko Higuchi Japan

Hasan Herken Türkiye

Anders Ettrup Denmark

William T. Regenold United States

Virginia L. Stauffer United States

James M. Martinez

2.3k ×1.6

PMH

296 ×0.6

PHARM

427 ×1.0

PHYSI

614 ×1.5

PFM

81 ×0.3

NEURO

Citations per year, relative to James M. Martinez James M. Martinez (= 1×) peers Virginia L. Stauffer

Countries citing papers authored by James M. Martinez

Since Specialization

Citations

This map shows the geographic impact of James M. Martinez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James M. Martinez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James M. Martinez more than expected).

Fields of papers citing papers by James M. Martinez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James M. Martinez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James M. Martinez. The network helps show where James M. Martinez may publish in the future.

Co-authorship network of co-authors of James M. Martinez

This figure shows the co-authorship network connecting the top 25 collaborators of James M. Martinez. A scholar is included among the top collaborators of James M. Martinez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James M. Martinez. James M. Martinez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tassorelli, Cristina, Tina M. Oakes, Jennifer Bardos, et al.. (2023). Baseline demographics and disease characteristics of patients with episodic or chronic cluster headache: data from two phase 3 randomized clinical trials in Europe and North America. Frontiers in Neurology. 14. 1293163–1293163. 1 indexed citations

Schwedt, Todd J., Tina M. Oakes, James M. Martinez, et al.. (2023). Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial. Neurology and Therapy. 13(1). 85–105. 19 indexed citations

Andrews, J. Scott, David Kudrow, Mallikarjuna Rettiganti, et al.. (2021). Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache. Journal of Pain Research. Volume 14. 2059–2070. 3 indexed citations

Goadsby, Peter J., David W. Dodick, James M. Martinez, et al.. (2019). Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. Journal of Neurology Neurosurgery & Psychiatry. 90(8). 939–944. 29 indexed citations

Nichols, Russell, J. Scott Andrews, James Jackson, et al.. (2019). Acute and preventive treatment patterns in episodic cluster headache: findings from the United States, United Kingdom and Germany (P5.10-015). Neurology. 92(15_supplement). 1 indexed citations

Bardos, Jennifer, Peter J. Goadsby, David W. Dodick, et al.. (2019). A Placebo-Controlled Study of Galcanezumab in Patients with Episodic Cluster Headache: Results from the 8-Week Double-Blind Treatment Phase (Plen02.004). Neurology. 92(15_supplement). 2 indexed citations

Aurora, Sheena K., Tina M. Oakes, Qi Zhang, Jonna Ahl, & James M. Martinez. (2017). Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab (P2.177). Neurology. 88(16_supplement). 1 indexed citations

Ahl, Jonna, Mark E. Bangs, Yingkai Cheng, et al.. (2013). The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports. Drug Healthcare and Patient Safety. 5. 211–211. 15 indexed citations

Martinez, James M., Wayne Katon, John H. Greist, et al.. (2011). A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. International Clinical Psychopharmacology. 27(1). 17–26. 25 indexed citations

10.

Gaynor, Paula J., Wei Zheng, James M. Martinez, et al.. (2011). Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study. Current Medical Research and Opinion. 27(10). 1859–1867. 27 indexed citations

11.

Goddard, Andrew W., Susan Ball, James M. Martinez, et al.. (2009). Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depression and Anxiety. 27(4). 339–350. 238 indexed citations

12.

Fava, Maurizio, James M. Martinez, Lauren B. Marangell, et al.. (2007). The Efficacy and Tolerability of Duloxetine in the Treatment of Anxious Versus Non-Anxious Depression: A Post-Hoc Analysis of an Open-Label Outpatient Study. Annals of Clinical Psychiatry. 19(3). 187–195. 20 indexed citations

13.

Martinez, James M. & Holly A. Zboyan. (2006). Vagus Nerve Stimulation Therapy in a Patient with Treatment-Resistant Depression: A Case Report of Long-Term Follow-up and Battery End-of-Service. CNS Spectrums. 11(2). 143–148. 7 indexed citations

14.

Marangell, Lauren B., et al.. (2005). Vagus nerve stimulation: A new tool for treating depression. 12(10). 40–43. 1 indexed citations

15.

Nahas, Ziad, Lauren B. Marangell, Mustafa M. Husain, et al.. (2005). Two-Year Outcome of Vagus Nerve Stimulation (VNS) for Treatment of Major Depressive Episodes. The Journal of Clinical Psychiatry. 66(9). 1097–1104. 266 indexed citations

16.

Wohlreich, Madelaine M., James M. Martinez, Craig Mallinckrodt, et al.. (2005). An Open-label Study of Duloxetine for the Treatment of Major Depressive Disorder. Journal of Clinical Psychopharmacology. 25(6). 552–560. 19 indexed citations

17.

Brown, Laurie M., et al.. (2004). BDNF protects against stress‐induced impairments in spatial learning and memory and LTP. Hippocampus. 15(2). 246–253. 166 indexed citations

18.

Marangell, Lauren B., James M. Martinez, Terence A. Ketter, et al.. (2004). Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP‐BD. Bipolar Disorders. 6(2). 139–143. 12 indexed citations

19.

Marangell, Lauren B., et al.. (2004). Omega-3 fatty acids for the prevention of postpartum depression: Negative data from a preliminary, open-label pilot study. Depression and Anxiety. 19(1). 20–23. 75 indexed citations

20.

Marangell, Lauren B., et al.. (2003). A Double-Blind, Placebo-Controlled Study of the Omega-3 Fatty Acid Docosahexaenoic Acid in the Treatment of Major Depression. American Journal of Psychiatry. 160(5). 996–998. 276 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact